IXICO plc IXICO to Present at SCA & ARCA Global Conference

TIDMIXI

IXICO plc

19 October 2020

This is an RNS Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

IXICO plc

("IXICO" or the "Company")

IXICO to Present at SCA & ARCA Global Conference

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , announces that Dr Robin Wolz, Senior Vice President of Science & Innovation at IXICO, will present on the industry panel at the virtual SCA & ARCA Global Conference, taking place on 19-21 October 2020.

The SCA & ARCA Global Conference brings together two initiatives that focus on ataxia, which is the loss of coordination of voluntary muscle movements. This platform allows for academic and industry leaders, physicians and companies working in the space to collaborate on developing future treatments for patients.

Autosomal-recessive cerebellar ataxias (ARCA) are a heterogeneous group of rare degenerative and metabolic genetic diseases recessively inherited and spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive ataxia disorders. The clinical manifestations of hereditary ataxias are poor coordination of movement and unsteady gait.

Dr Robin Wolz will be presenting on the industry panel on 20 October at 16.20 (BST). The talk is titled: "Challenges and opportunities in the deployment of volumetric MRI in SCA clinical trials ." Additionally, IXICO are supporting the conference as an official partner of SCA & ARCA Global 2020.

Dr Robin Wolz, Senior Vice President, Science & Innovation at IXICO commented: "Ataxia conditions continue to be a focus for IXICO in its efforts to provide pioneering technologies to support the advancement of effective treatments for rare neurological diseases. Our research in imaging analytics will provide an insight into the best methods for monitoring both the progression of the disease as well as the potential effect of interventional treatments."

Additional info can be found on the conference website: http://ataxia-global-initiatives.net/sca-global/conferences/sca-global-2020/

For further information please contact:

 
 IXICO plc                                                                          [phone] 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                                                  [phone] 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Russell Kerr 
  (Sales) 
 
 Walbrook PR Ltd                                      Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne / Alice Woodings 
 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com and follow us on Twitter @IxicOplc

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAZZMMGRVDGGZM

(END) Dow Jones Newswires

October 19, 2020 02:00 ET (06:00 GMT)